NBIX earnings call for the period ending December 31, 2018.
News & Analysis: Neurocrine Biosciences
The company just licensed four drug programs for a cool $165 million up-front payment -- with the potential to receive $1.7 billion in future milestone payments.
Earnings per share will more than double for each of these specialty drugmakers.
Find out which of these companies warned about its future results.
Shares fall hard after the company reports disappointing data from an important clinical trial.
Ignoring these promising biotech stocks could be a mistake.
This fast-growing biotech is on track for significant earnings growth.
The company reported second-quarter 2018 results.
Looking for a few timely buys in the biotech space? Give these gems a closer look.
April showers might bring May flowers. But they also bring major FDA decisions for these biotechs.